CommScope Holding is a provider of infrastructure solutions for communication networks. The company's solutions and services for wired and wireless networks enable high-bandwidth data, video and voice applications. The company's operating segments are: CommScope Connectivity Solutions (CCS) and CommScope Mobility Solutions (CMS). The CCS segment is engaged in providing fiber optic and copper connectivity solutions for use in data centers and business enterprise, telecommunications, cable television and residential broadband networks. The CMS segment is engaged in providing infrastructure for wireless networks.

Full House Resorts owns, leases, operates, develops, manages, and/or invests in casinos and related hospitality and entertainment facilities. The company manages its casinos based on geographic regions within the U.S. The casino/resort operations includes four segments: the Silver Slipper Casino and Hotel (Hancock County, MI); Bronco Billy's Casino and Hotel (Cripple Creek, CO); the Rising Star Casino Resort (Rising Sun, IN); and the Northern Nevada segment, consisting of the Grand Lodge Casino (Incline Village, NV) and Stockman's Casino (Fallon, NV).

Gannett owns, operates and invests in local media assets focused in small to mid-size markets. The company's main products include: daily newspapers; weekly newspapers, which publishe up to three times per week; shoppers, which are generally advertising-only publications; locally-focused websites, which extend the company's businesses onto the internet and mobile devices; business publications; UpCurve Cloud and ThriveHive digital marketing; and GateHouse Live. In addition to its main products, the company also produces publications that address specific local market interests such as recreation, sports, healthcare and real estate.

Inter Parfums operates in the fragrance business, and manufactures, markets and distributes a range of fragrance and fragrance related products. The company manages its business in two segments, European based operations, which produces and distributes its fragrance products primarily under license agreements with brand owners, and fragrance product sales, as well as built a portfolio of brands, which include Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Lanvin, Montblanc, Paul Smith, and Repetto; and U.S. based operations, which brand fragrance products are sold under trademarks owned by the company or pursuant to license or other agreements with the owners of brands, which include Abercrombie & Fitch.

RGC Resources is a holding company. Through its subsidiaries, the company is an energy services company primarily engaged in the sale and distribution of natural gas. The company's wholly owned subsidiaries include: Roanoke Gas Company (Roanoke Gas); Diversified Energy Company; and RGC Midstream, LLC (Midstream). Roanoke Gas is a natural gas utility, which distributes and sells natural gas to residential, commercial and industrial customers within its service areas in Roanoke, VA and the surrounding localities. Diversified Energy Company is inactive. Midstream is an investor in Mountain Valley Pipeline, LLC, which was created to construct and operate interstate natural gas pipelines.

Saul Centers operates as a real estate investment trust. The company, which conducts its activities through its subsidiaries, the Saul Holdings Limited Partnership and two subsidiary limited partnerships, engages in the ownership, operation, management, leasing, acquisition, renovation, expansion, development and financing of community and neighborhood shopping centers and mixed-used properties, primarily in the Washington, DC/Baltimore metropolitan area. The company's properties consist of shopping center properties, mixed-use properties, which are comprised of office, retail and multi-family residential uses and development properties.

TG Therapeutics is a biopharmaceutical company focuses on developing and delivering medicines for patients with B-cell mediated diseases, including Chronic Lymphocytic Leukemia (CLL), non-Hodgkin's Lymphoma (NHL) and Multiple Sclerosis (MS). The company has developed a B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. The company has five B-cell targeted drug candidates in clinical development, with the two therapies, ublituximab (TG-1101) and umbralisib (TGR-1202), in pivotal trials for CLL, NHL and MS. Ublituximab is an anti-CD20 monoclonal antibody. Umbralisib is an oral, once daily inhibitor of PI3K delta.